ASTRAZENECA PHARMA IND LT

Imports and markets AstraZeneca's prescription drugs in India across three therapy areas. Oncology generated Rs 16,101 million in FY26 (up 44% year on year), led by cancer drugs such as Enhertu and Tagrisso sold to hospital oncologists. Biopharmaceuticals contributed Rs 5,243 million (up 7.2%), covering biologic medicines such as Fasenra. Rare Disease was Rs 215 million, up sevenfold. The company exited its Bengaluru manufacturing operations during the year, so all products are now imported and distributed through a marketing organisation of 760 permanent employees. Eleven new regulatory approvals were secured in FY26, including label extensions for Enhertu (neoadjuvant HER2-positive breast cancer) and Fasenra (Hypereosinophilic Syndrome). Employee costs are the largest stated operating expense at 11.6% of revenue, followed by other operating expenses at 16.2%. The business carries exposure to price control litigation under DPCO 2013 - NPPA has issued demand notices alleging overcharging on Symbicort Turbuhaler 160/4.5 (Rs 148.66 crore inclusive of interest) and Betaloc-50 tablets (Rs 79.97 lakh), both of which the company is reviewing.